Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

• Автори: Isla D (Автор), De Castro J (Автор), Juan O (Автор), Grau S (Автор), Orofino J (Автор), Gordo R (Автор), Rubio-Terrés C (Автор), Rubio-Rodríguez D (Автор)
• Формат: Книга
• Опубліковано: Dove Medical Press, 2016-12-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Dolores Isla,1 Javier De Castro,2 Oscar Juan,3 Santiago Grau,4 Javier Orofino,5 Rocío Gordo,5 Carlos Rubio-Terrés,6 Darío Rubio-Rodríguez6 1Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza, 2Medical Oncology Department, Universitary Hospital La Paz, Madrid, 3Medical...